<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="GBP" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-GOV-13-FUND--Newton-MR_N007085_1</iati-identifier>
  <reporting-org ref="GB-GOV-13" type="10">
   <narrative xml:lang="EN">Department of Business, Energy and Industrial Strategy</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">&quot;Newton001&quot; The effects of tetrathiomolybdate, a donator of hydrogen sulphide, in animal models of brain ischemia</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Ischaemia (low oxygen) occurs when blood flow to a vital organ (e.g., heart, brain) is insufficient to meet metabolic demand. This leads to death of tissue and loss of function (i.e., as in heart attack, stroke). Presently, there are limited strategies to deal with ischaemia. Although reopening blood vessels (reperfusion) is a necessary, often lifesaving treatment that improves long-term outcome, &apos;reperfusion injury&apos; upon restoration of blood supply can cause further damage. Attempts to decrease reperfusion injury have recently focussed on decreasing metabolism. For example, after cardiac arrest and resuscitation, decreasing body temperature (therapeutic hypothermia) may have a protective effect, although this takes time to initiate. Giving a drug that can decrease metabolism more rapidly could provide added benefit in this scenario. Hydrogen sulphide given either in gas form or intravenously could induce a state of &apos;suspended animation&apos; in mice with marked reductions in core temperature and metabolic rate (Blackstone, Science 2005). However, this was far less effective in modulating metabolism in larger species, including rats. We made the novel discovery that the copper-modulating drug, tetrathiomolybdate (TTM), was a slow-releaser or hydrogen sulphide, and could safely induce suspended animation in rats, whereas native hydrogen sulphide had no effect, or toxicity at high doses. We previously found that, when used just prior to resuscitation in a severe haemorrhage-reperfusion injury rat model, mortality was halved. We also found benefit in a heart ischaemia-reperfusion model with a 43% reduction in damaged heart tissue. We wish to extend our findings to explore outcomes in animal models of brain ischaemia. We will focus on mechanisms associated with brain protection after TTM treatment, such as brain inflammation and cognitive performance.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">To determine the efficacy of tetrathiomolybdate in the treatment of brain ischaemia in animal models To determine the effects of tetrathiomolybdate on brain inflammation and oxidative stress in these model To determine the effects of tetrathiomolybdate on brain mitochondrial function and temperature in these model  To determine the effects of tetrathiomolybdate on cognitive outcomes in these models</narrative>
  </description>
  <participating-org ref="GB-GOV-13" role="1" type="10">
   <narrative xml:lang="EN">UK - Department for Business, Energy and Industrial Strategy</narrative>
  </participating-org>
  <participating-org role="3" type="90">
   <narrative xml:lang="EN">UK Research &amp; Innovation</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University College London</narrative>
  </participating-org>
  <activity-status code="3"></activity-status>
  <activity-date iso-date="2015-04-13" type="1"></activity-date>
  <activity-date iso-date="2015-04-13" type="2"></activity-date>
  <activity-date iso-date="2016-04-12" type="3"></activity-date>
  <activity-date iso-date="2016-07-12" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">UK Research &amp; Innovation</narrative>
   </organisation>
   <department>
    <narrative xml:lang="EN">International Development</narrative>
   </department>
   <person-name>
    <narrative xml:lang="EN">Newton</narrative>
   </person-name>
   <email>gcrf@ukri.org</email>
   <website>https://www.ukri.org/</website>
   <mailing-address>
    <narrative xml:lang="EN">Polaris House, Swindon, SN2 1LF</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="BR" percentage="100">
   <narrative xml:lang="EN">Brazil</narrative>
  </recipient-country>
  <recipient-region code="489" percentage="100" vocabulary="1"></recipient-region>
  <sector code="43082" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Research/scientific institutions</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="2" type="1">
   <period-start iso-date="2015-04-01"></period-start>
   <period-end iso-date="2016-03-31"></period-end>
   <value currency="GBP" value-date="2015-03-30">36291.64</value>
  </budget>
  <capital-spend percentage="0"></capital-spend>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2015-03-30"></transaction-date>
   <value currency="GBP" value-date="2015-03-30">580666.24</value>
   <description>
    <narrative xml:lang="EN">MRC Newton Strategic Awards Award to University College London</narrative>
   </description>
   <provider-org provider-activity-id="GB-GOV-13-FUND--Newton-MR_N007085_1" ref="GB-GOV-13">
    <narrative xml:lang="EN">UK Research &amp; Innovation</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">University College London</narrative>
   </receiver-org>
  </transaction>
  <document-link format="APPLICATION/HTTP" url="http://gtr.ukri.org/projects?ref=MR%2FN007085%2F1">
   <title>
    <narrative xml:lang="EN">Abstract/Planned Impact</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
   <document-date iso-date="2015-04-13"></document-date>
  </document-link>
  <document-link format="APPLICATION/PDF" url="https://www.ukri.org/funding/information-for-award-holders/grant-terms-and-conditions/">
   <title>
    <narrative xml:lang="EN">UK Research &amp; Innovation Grant Terms and Conditions</narrative>
   </title>
   <category code="A04"></category>
  </document-link>
  <conditions attached="1"></conditions>
 </iati-activity>
</iati-activities>
